ArticleAdvances in urology2026
Real-World Outcomes of Combination Therapy With Radium-223 and Enzalutamide Compared With Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer.
Article in Advances in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radium-223 and enzalutamide have shown survival benefits in metastatic castration-resistant prostate cancer, and recent trial data suggest a potential synergy in combination. However, real-world data on their combined use, especially regarding fracture risk and prior androgen receptor signaling inhibitor exposure, are limited. In this study, we aimed to evaluate the efficacy and safety of adding radium-223 to enzalutamide compared with enzalutamide alone in patients with bone metastatic castration-resistant prostate cancer. We retrospectively included patients treated with radium-223 plus enzalutamide (the combination group) or enzalutamide alone (the enzalutamide group), and compared progression-free survival, overall survival, prostate-specific antigen kinetics, alkaline phosphatase kinetics, and treatment-emergent adverse events. A total of 17 and 18 patients were included in the combination and enzalutamide groups, and the median age and follow-up duration were 75 years and 23 months, respectively. The median progression-free survival was significantly longer in the combination group (22 months [95% confidence interval (CI): 16.7-32.4]) than that in the enzalutamide group (5 months [95% CI: 6.3-25.2],
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.